Treatment of aggressive adult T-cell leukemia/lymphoma: a retrospective study in a hospital located in HTLV-1 highly endemic area.

Deltaretrovirus Infections / epidemiology Disease Progression Hospitals / statistics & numerical data Human T-lymphotropic virus 1 Humans Leukemia-Lymphoma, Adult T-Cell / epidemiology Retrospective Studies
ATL HTLV-1 OPEC/MPEC RDI VCAP-AMP-VECP

Journal

International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 14 06 2019
accepted: 29 10 2019
revised: 21 10 2019
pubmed: 14 11 2019
medline: 11 8 2020
entrez: 14 11 2019
Statut: ppublish

Résumé

Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell neoplasm associated with the human T-cell leukemia virus type-I (HTLV-1); prognosis still remains very poor. We retrospectively reviewed the treatment of 198 patients with acute-, lymphoma- and unfavorable chronic-type ATL (aggressive ATL) diagnosed from 2005 to 2014 in a hospital located in an area of Japan in which HTLV-1 is highly endemic. One-hundred forty-three, and 35 patients were treated using OPEC/MPEC and VCAP-AMP-VECP, respectively. OPEC/MPEC was mainly used until around 2010, and gradually switched to VCAP-AMP-VECP, especially for younger patients. The 2-year overall survival for patients treated by VCAP-AMP-VECP was significantly higher than that using OPEC/MPEC for patients < 70 years old (y.o.), but not for patients ≥ 70 y.o. A less intensive chemotherapy OPEC/MPEC could be performed without reducing dose intensity, even in elderly patients, and its therapeutic outcome is not inferior to that of VCAP-AMP-VECP. It is difficult to draw definite conclusion from this small retrospective study; however, OPEC/MPEC may represent an alternative option for elderly patients with aggressive ATL.

Identifiants

DOI: 10.1007/s12185-019-02769-w PMID: 31721034
pubmed: 31721034
doi: 10.1007/s12185-019-02769-w
pii: 10.1007/s12185-019-02769-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

234-240

Commentaires et corrections

Type : ErratumIn

Références

Br J Haematol. 1991 Nov;79(3):428-37
pubmed: 1751370
J Clin Oncol. 2016 Dec;34(34):4086-4093
pubmed: 27621400
Br J Haematol. 2015 Jun;169(5):672-82
pubmed: 25733162
Blood. 1977 Sep;50(3):481-92
pubmed: 301762
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Int J Hematol. 2018 Apr;107(4):420-427
pubmed: 29502313
Blood. 2015 Dec 10;126(24):2570-7
pubmed: 26361794
J Clin Oncol. 2009 Jan 20;27(3):453-9
pubmed: 19064971
Lancet Oncol. 2014 Oct;15(11):e517-26
pubmed: 25281470
J Clin Oncol. 2007 Dec 1;25(34):5458-64
pubmed: 17968021
J Clin Oncol. 2012 Mar 10;30(8):837-42
pubmed: 22312108
Leuk Lymphoma. 1999 Dec;36(1-2):67-75
pubmed: 10613451
Int J Hematol. 2014 Nov;100(5):464-72
pubmed: 25209605
Br J Haematol. 2001 May;113(2):375-82
pubmed: 11380402
J Clin Oncol. 2012 May 10;30(14):1635-40
pubmed: 22473153
Cancer Sci. 2017 Dec;108(12):2478-2486
pubmed: 28905463
Lancet Infect Dis. 2016 Nov;16(11):1246-1254
pubmed: 27567105

Auteurs

Daisuke Nakamura (D)

Department of Hematology, Izuro Imamura Hospital, 17-1 Horie, Kagoshima, Japan. d5039@m3.kufm.kagoshima-u.ac.jp.
Department of Hematology and Rheumatology, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima, Japan. d5039@m3.kufm.kagoshima-u.ac.jp.

Makoto Yoshimitsu (M)

Department of Hematology and Rheumatology, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima, Japan.

Tomohisa Tabuchi (T)

Department of Hematology, Izuro Imamura Hospital, 17-1 Horie, Kagoshima, Japan.
Department of Hematology and Rheumatology, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima, Japan.

Naosuke Arima (N)

Department of Hematology, Izuro Imamura Hospital, 17-1 Horie, Kagoshima, Japan.
Department of Hematology and Rheumatology, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima, Japan.

Maiko Hayashida (M)

Department of Hematology, Izuro Imamura Hospital, 17-1 Horie, Kagoshima, Japan.
Department of Hematology and Rheumatology, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima, Japan.

Hirosaka Inoue (H)

Department of Hematology, Izuro Imamura Hospital, 17-1 Horie, Kagoshima, Japan.
Department of Hematology and Rheumatology, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima, Japan.

Kakushi Matsushita (K)

Department of Hematology, Izuro Imamura Hospital, 17-1 Horie, Kagoshima, Japan.
Department of Hematology and Rheumatology, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima, Japan.

Tadashi Matsumoto (T)

Department of Hematology, Izuro Imamura Hospital, 17-1 Horie, Kagoshima, Japan.

Naomichi Arima (N)

Department of Hematology and Rheumatology, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima, Japan.

Kenji Ishitsuka (K)

Department of Hematology and Rheumatology, Kagoshima University Hospital, 8-35-1 Sakuragaoka, Kagoshima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à deltarétrovirus › Treatment of aggressive adult T-cell...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Treatment of aggressive adult T-cell...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Établissements de santé › Hôpitaux › Treatment of aggressive adult T-cell...
questionsmedicales.fr › Virus › Virus à ARN › Retroviridae › Deltaretrovirus › Virus T-lymphotrope de type 1 des primates › Virus T-lymphotrope humain de type 1 › Treatment of aggressive adult T-cell...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Treatment of aggressive adult T-cell...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Leucémie lymphoïde › Leucémie à cellules T › Leucémie-lymphome à cellules T de l'adulte › Treatment of aggressive adult T-cell...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Treatment of aggressive adult T-cell...